Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.

SGLT2 Inhibitors and GLP-1 Receptor Agonists: Indications – American College of Cardiology

Original review: SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications – The Lancet (link to abstract – $ for full-text)

Related guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.